The Strategy of Development of Highly Specific Antiviral Therapeutics
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Targeting and Design".
Deadline for manuscript submissions: closed (20 December 2021) | Viewed by 377
Special Issue Editors
Interests: biopolymers; pharmaceutics; bioconjugation; bioanalysis; ligand–receptor interactions; peptides; drug delivery
Special Issues, Collections and Topics in MDPI journals
2. Department of General and Bioorganic Chemistry, First Pavlov Saint Petersburg State Medical University, 199034 Saint Petersburg, Russia
Interests: biochemistry; bioorganic chemistry; medicine chemistry; cell and molecular biology; biomimetic materials; pharmacytes; click chemistry; hybrid materials; carbon nanomaterials; nanotechnology; theranostics; drug delivery; anticancer agents; tumor microenvironment; inflammation; molecular metabolism; signal transduction; mitochondria; oxidative stress; DNA damage; bioassays; biomolecular interactions; isothermal titration calorimetry; fluorescence thermal shift; flow cytofluorimetry; biological activity of compounds; cancer; diabetes; preclinical animal models
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
The emergence of viral diseases is expected to accelerate in recent years. These data dictate the need for active approaches to the development of widely active family-specific and cross-family therapies for use in future disease outbreaks. Advances in this area have been achieved through efforts and technical discoveries in various fields of science. The focus should be not only on the development of broad-spectrum, low-molecular-weight antivirals and direct-acting antibodies, but also on therapeutics associated with host factors, including the repurposing of previously approved or under development drugs. This Special Issue aims at the strategy of the development of highly specific antiviral therapeutics based on anti- and nanobodies, RNA, DNA, and peptide aptamers, siRNA, anti-sense oligos, and small organic molecules. Pharmaceutics is open to both original research articles and review articles focusing on the strategy of development of highly specific antiviral therapeutics. We look forward to receiving your contributions.
Prof. Dr. Tatiana B. Tennikova
Dr. Vladimir V. Sharoyko
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- drug design
- antiviral agents
- antiviral targets
- viral glycoproteins
- receptor–ligand interactions
- host–pathogen interactions
- therapeutics
